Figure 1. The model that we propose—based on our results—postulates that mBD14, expressed by host-derived CD45⁺ hematopoietic cells, recruits activated B220⁺/CD19⁺ B cells into tumors in a CCR6-dependent manner. These B cells, expressing LTβR-ligands, activate LTβR on tumor cells, in turn promoting CXCL2 expression, enhanced angiogenesis and increased tumor growth.